JCS Medical, Change of Major Shareholder
JCS Medical announced on the 10th that its largest shareholder is scheduled to change to Syracuse Subco.
Syracuse Subco is a corporation newly established in Korea by Archimed in April, and it announced that from this day until the 22nd of next month, it will conduct a tender offer to purchase 55,724,838 common shares of JCS Medical at 13,000 KRW per share. This corresponds to 72.0% of the total potential issued shares of JCS Medical.
The total amount is approximately 724.4 billion KRW, and NH Investment & Securities is the lead manager for the tender offer.
Hot Picks Today
!["Big Gains for Holders... Up 566% and Still More to Go" Target Price Raised, But Here’s Why Caution Remains [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2025090513580721483_1757048288.jpg)
"Big Gains for Holders... Up 566% and Still More to Go" Target Price Raised, But Here’s Why Caution Remains [Weekend Money]
- "Data Centers Ignite ESS Order Rally Expectations for This Company [Weekend Money]"
- "Achieving 1 Billion Won Through Stocks" Office Worker Remains Optimistic Despite Mandatory Paid Leave and Halved Salary
- Every Show Sold Out in North America... How Much Did BTS Earn from the Tour?
- "Best Homeroom Teacher"... Hong Kong Education Sector in Shock Over Spread of "Princess Carry" Photos
Archimed is a France-based private equity fund management company established in 2014, primarily investing in the healthcare sector including bio-pharmaceuticals, medical technology, and in vitro diagnostics.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
